RxSight (RXST)

• Market cap: $619M
• 1 day: 4.67%
• 5 days: 3.11%
• 1 month: -39.64%
• 3 months: -51.74%
• 6 months: -70.78%
• Year to date: -55.89%
• 1 year: -71.39%
• 5 years: -4.75%
• 10 years: -4.75%
• Sector: Healthcare
• Industry: Medical Devices

About: RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Employees: 498

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1,042% more call options, than puts

Call options by funds: $19.8M | Put options by funds: $1.73M

50% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]

35% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 62

2.11% more ownership

Funds ownership: 85.54% [Q3] → 87.65% (+2.11%) [Q4]

5% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 41

1% less funds holding

Funds holding: 214 [Q3] → 211 (-3) [Q4]

28% less capital invested

Capital invested by funds: $1.68B [Q3] → $1.21B (-$463M) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $16 5% upside
• Avg. target: $22 44% upside
• High target: $36 136% upside

7 analyst ratings

• positive: 2 29%
• neutral: 4 57%
• negative: 1 14%

Piper Sandler Adam Maeder 54% 1-year accuracy 7 / 13 met price target	18% upside $18	Neutral Initiated	15 Apr 2025
UBS Danielle Antalffy 55% 1-year accuracy 6 / 11 met price target	5% upside $16	Neutral Downgraded	9 Apr 2025
Needham David Saxon 38% 1-year accuracy 25 / 65 met price target	44% upside $22	Buy Maintained	8 Apr 2025
Wells Fargo Larry Biegelsen 27% 1-year accuracy 12 / 44 met price target	12% upside $17	Equal-Weight Maintained	7 Apr 2025
JP Morgan Robbie Marcus 35% 1-year accuracy 6 / 17 met price target	12% upside $17	Underweight Downgraded	4 Apr 2025